Market Overview

Earnings Preview For MyoKardia

Related MYOK
The Daily Biotech Pulse: Foamix Jumps on Data, Positive Results for Galapagos-Gilead's Rheumatoid Arthritis Drug, Bausch Health Trims Debt
The Daily Biotech Pulse: Advaxis Posts Narrower Loss, Endocyte Announces $175M Offering, Leadership Transition At Insulet

MyoKardia, Inc. - Common Stock (NASDAQ: MYOK) announces its next round of earnings Thursday. Here is Benzinga's everything-that-matters guide for today's Q4 earnings announcement.

Earnings and Revenue

Based on management's projections, MyoKardia analysts modeled for a loss of 41 cents per share on sales of $6.08 million.

If the company were to post earnings inline with the consensus estimate when it reports Thursday, EPS would be up 24.24 percent. Sales would be up 71.27 percent from the year-ago period.

Here's how the company's reported EPS has stacked up against analyst estimates in the past:


Quarter Q3 2017 Q2 2017 Q1 2017 Q4 2016
EPS Estimate -0.41 -0.37 -0.31 -0.18
EPS Actual -0.42 -0.41 -0.37 -0.33


Stock Performance

Over the last 52-week period, shares are up 358.1 percent. Given that these returns are generally positive, long-term shareholders should be content going into this earnings release.

Analyst estimates are adjusted lower for EPS and revenues over the past 90 days. The popular rating by analysts on MyoKardia stock is a Neutral. The strength of this rating has maintained conviction over the past 90 days.

Conference Call

MyoKardia's conference call is scheduled to begin at 4:30 p.m. ET and can be accessed here.

Posted-In: Earnings News Previews Trading Ideas


Related Articles (MYOK)

View Comments and Join the Discussion!

OncoMed Pharmaceuticals Q4 Earnings Preview

Codexis Q4 Earnings Preview